Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 | P54289 | 10/20 | 0.50 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.49 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | NSD2 | O96028 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6308046 | 0.81 | F9 (0.47) | CACNA2D1KCNA3LMNAKDM4EMAPKAPK2 | |
| SCHEMBL5792721 | 0.81 | KMT2A (0.48) | CACNA2D1KCNA3KDM4EMAPKAPK2NR3C1 | |
| SCHEMBL5792709 | 0.81 | KMT2A (0.48) | CACNA2D1KCNA3KDM4EMAPKAPK2NR3C1 | |
| SCHEMBL96459 | 0.80 | MAPT (0.58) | CACNA2D1KCNA3LMNAKDM4ECYP1A2 | |
| SCHEMBL5792713 | 0.79 | CACNA2D1 (0.43) | CACNA2D1KCNA3LMNAKDM4EMAPKAPK2 | |
| SCHEMBL11139798 | 0.79 | CYP1A2 (0.46) | KCNA3CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4517253 | 0.78 | KCNA3 (0.56) | CACNA2D1KCNA3LMNAKDM4ECYP1A2 | |
| SCHEMBL4982131 | 0.77 | CYP1A2 (0.56) | KDM4ECYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL96458 | 0.77 | KCNA3 (0.54) | CACNA2D1KCNA3LMNAKDM4ECYP1A2 | |
| SCHEMBL27535690 | 0.76 | KCNA3 (0.55) | CACNA2D1KCNA3LMNAKDM4ECYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220072019-A1 | INHIBITORS OF SARM1 IN COMBINATION WITH NAD+ OR A NAD+ PRECURSOR | DISARM THERAPEUTICS, INC. | 2022-03-10 | — | — | US | disclosed |
| US-20220008405-A1 | INHIBITORS OF SARM1 IN COMBINATION WITH NEURO-PROTECTIVE AGENTS | DISARM THERAPEUTICS, INC. | 2022-01-13 | — | — | US | disclosed |
| WO-2020132045-A1 | INHIBITORS OF SARM1 IN COMBINATION WITH NEUROPROTECTIVE AGENTS | DISARM THERAPEUTICS, INC. (US) | 2020-06-25 | — | — | WO | disclosed |
| WO-2020081923-A1 | INHIBITORS OF SARM1 IN COMBINATION WITH NAD+ OR A NAD+ PRECURSOR | DISARM THERAPEUTICS, INC. (US) | 2020-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220072019-A1 | INHIBITORS OF SARM1 IN COMBINATION WITH NAD+ OR A NAD+ PRECURSOR | SARM1, NNMT, NQO1 | CACNA2D1 4322/4885KCNA3 4476/4885LMNA 1261/4885 |
| US-20220008405-A1 | INHIBITORS OF SARM1 IN COMBINATION WITH NEURO-PROTECTIVE AGENTS | SARM1, SMN1; SMN2, SARNP | CACNA2D1 4509/4885KCNA3 4487/4885LMNA 1527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.